Compounds > apricoxib
Page last updated: 2024-12-11

apricoxib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

apricoxib: a COX-2 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9820073
CHEMBL ID1835207
SCHEMBL ID346028
MeSH IDM0503331

Synonyms (37)

Synonym
apricoxib
197904-84-0
apricoxib (usan/inn)
D08657
5x5hb3vz3z ,
r 109339
apricoxib [usan:inn]
4-(2-(4-ethoxyphenyl)-4-methyl-1h-pyrrol-1-yl)benzenesulfonamide
cs 706
unii-5x5hb3vz3z
cs706 cpd
2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1h-pyrrole
benzenesulfonamide, 4-(2-(4-ethoxyphenyl)-4-methyl-1h-pyrrol-1-yl)-
tg 01
tg01
CHEMBL1835207
r-109339
tg-01
cs-706
kymena
capoxigem
tp-1001
tp-2001
apricoxib [usan]
apricoxib [who-dd]
4-[2-(4-ethoxyphenyl)-4-methyl-1h-pyrrol-1-yl]benzenesulfonamide
apricoxib [inn]
SCHEMBL346028
JTMITOKKUMVWRT-UHFFFAOYSA-N
2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole
DTXSID60173502
DB12378
4-[2-(4-ethoxyphenyl)-4-methylpyrrol-1-yl]benzenesulfonamide
Q18209480
cs 706; r 109339; tg 01
4-methyl-2-(4-ethoxyphenyl)-1-(4-sulfamoylphenyl)pyrrole
cs701

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"A predictive population pharmacokinetic model was developed for a novel cyclooxygenase-2 (COX-2) inhibitor CS-706, using data from 130 subjects in 3 phase 1 trials after single or multiple doses of CS-706 (2- to 800-mg doses daily, up to 14 days) and validated using sparse data from a separate study."( Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor.
Gao, Y; Kastrissios, H; Kawabata, K; Moberly, J; Rohatagi, S; Salazar, D; Takahashi, M; Truitt, K; Wada, R, 2006)		0.33
"The objectives of these analyses were to (1) develop a population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor (CS-706) using data from primarily Caucasian subjects, (2) predict responses in subpopulations of interest (including Japanese subjects), and (3) correlate pharmacodynamic parameters to safety outcomes."( Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor.
Gao, Y; Kastrissios, H; Moberly, J; Rohatagi, S; Salazar, D; Takahashi, M; Truitt, K; Wada, R; Xu, J; Yoshihara, K; Zhang, N, 2007)		0.34

Compound-Compound Interactions

Apricoxib, a novel once-daily selective cyclooxygenase-2 inhibitor, was investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer.

ExcerptReferenceRelevance
" Administration of 30 mg/kg CS-706 from Day 7 combined with a single intravenous treatment of 10 mg/kg cisplatin on Day 7 completely regressed the tumors in all tumor-bearing mice examined, whereas only in 1 of 10 mice tumor was regressed with cisplatin treatment."( CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
Fujiwara, K; Hanai, M; Inoue, S; Ishida, S; Kimura, T; Kurakata, S; Senzaki, M; Yada, A, 2008)		0.35
"Apricoxib, a novel once-daily selective cyclooxygenase-2 inhibitor, was investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer to determine the maximum tolerated dose, dose-limiting toxicity, and recommended phase II dose (RP2D) based on changes in urinary prostaglandin E₂ metabolite (PGE-M)."( Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S, 2011)		2.03
"Patients received escalating doses of apricoxib (100, 200, and 400 mg/day) in combination with erlotinib 150 mg/day until disease progression or unacceptable toxicity."( Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S, 2011)		0.86
" This randomized phase 2 trial evaluated apricoxib, a novel COX-2 inhibitor, in combination with erlotinib in biomarker-selected patients."( A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S, 2014)		0.89
" Docetaxel 75 mg/m(2) or pemetrexed 500 mg/m(2) once every 21 days per the investigator was administered with apricoxib or placebo 400 mg once per day."( Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.
de Mayolo, JA; Edelman, MJ; Evans, TL; Feliciano, J; Fidler, MJ; Keresztes, R; Medeiros, M; Otterson, G; Rogers, JS; Sanborn, RE; Schneider, BJ; Sequist, LV; Tan, MT; Yang, Y; Zaknoen, SL, 2015)		0.84

Bioavailability

ExcerptReferenceRelevance
" Bioavailability increased by 42% after nighttime doses and decreased saturably with increasing dose (50% reduction at 221 mg)."( Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor.
Gao, Y; Kastrissios, H; Kawabata, K; Moberly, J; Rohatagi, S; Salazar, D; Takahashi, M; Truitt, K; Wada, R, 2006)		0.33

Dosage Studied

ExcerptRelevanceReference
" In contrast, naproxen nearly completely inhibited COX-1 over the dosing interval."( A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.
Breese, T; Dale, JC; Harris, SI; Lawson, J; McLaughlin, P; Moberly, JB; Riff, DS; Truitt, KE; Wan, Y; Xu, J, 2007)		0.34
" The onset of analgesia (PID >or= 1) for all CS-706 doses occurred within 1 hour after dosing (P<0."( A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.
Bandy, DP; Daniels, SE; Desjardins, PJ; Lawson, JE; Link, AJ; Moberly, JB; Truitt, KE; Xu, J, 2007)		0.34
"The set of models developed permitted compilation of multiple dose-response curves for dose selection of CS-706 in Westerners and facilitated scaling of doses to a Japanese population."( Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.
Kastrissios, H; Moberly, JB; Rohatagi, S; Salazar, DE; Sasahara, K; Truitt, K; Wada, R, 2008)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID623148Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells assessed as PGE2 level per 1000 cells at 10 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 3.15 +/- 0.19 pg/mL)2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
AID623146Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells assessed as PGE2 level per 1000 cells at 0.1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 3.15 +/- 0.19 pg/mL)2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
AID623151Inhibition of sodium arachidonate-induced PGE2 production in human SUM190 cells assessed as PGE2 level per 1000 cells at 10 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 6.43 +/- 1.87 pg/mL)2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
AID623150Inhibition of sodium arachidonate-induced PGE2 production in human SUM190 cells assessed as PGE2 level per 1000 cells at 1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 6.43 +/- 1.87 pg/mL)2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
AID623154Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells at 10 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
AID623153Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells at 1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
AID623149Inhibition of sodium arachidonate-induced PGE2 production in human SUM190 cells assessed as PGE2 level per 1000 cells at 0.1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 6.43 +/- 1.87 pg/mL)2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
AID623147Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells assessed as PGE2 level per 1000 cells at 1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 3.15 +/- 0.19 pg/mL)2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
AID623152Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells at 100 nM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (57.89)29.6817
2010's8 (42.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.77 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (36.84%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (57.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
melatonin
[no description available]		3.1310acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
celecoxib
[no description available]		4.1231organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0410nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
rofecoxib
[no description available]		2.0310butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		10.25197pyrrole;
secondary amine
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		5.6332azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		4.4111secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		3.4211methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid
[no description available]		6.4733prostanoid
erlotinib hydrochloride
[no description available]		5.6332hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
elastin
[no description available]		2.0310oligopeptide
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		2.0610aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.9640prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
thromboxane b2
Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.		2.0310thromboxanes Bhuman metabolite;
mouse metabolite
transforming growth factor alpha
Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.		3.1310
guanine
[no description available]		4.41112-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		9.4111N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Inflammatory Breast Cancer
[description not available]		07.0610
Inflammatory Breast Neoplasms
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.		02.0610
Disease Exacerbation
[description not available]		04.411
Adenocarcinoma, Basal Cell
[description not available]		04.7721
Adenocarcinoma, Alveolar
[description not available]		04.411
Carcinoma, Non-Small Cell Lung
[description not available]		06.4733
Carcinoma, Epidermoid
[description not available]		04.7921
Cancer of Lung
[description not available]		06.4733
Local Neoplasm Recurrence
[description not available]		04.411
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		04.7721
Adenocarcinoma, Bronchiolo-Alveolar
A carcinoma derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)		04.411
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		18.4733
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		04.7921
Lung Neoplasms
Tumors or cancer of the LUNG.		06.4733
Acute Post-operative Pain
[description not available]		04.3922
Pain, Postoperative
Pain during the period after surgery.		04.3922
Innate Inflammatory Response
[description not available]		03.3620
Benign Neoplasms
[description not available]		02.9610
Ache
[description not available]		03.3620
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		03.3620
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.9610
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		08.3620
Cancer of Pancreas
[description not available]		02.4720
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		14.4720
Carcinoma, Squamous Cell of Head and Neck
[description not available]		02.0710
Cancer of Head
[description not available]		02.0710
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		02.0710
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.0710
Metastase
[description not available]		02.0710
Angiogenesis, Pathologic
[description not available]		02.0710
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.0710
Curling Ulcer
Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.		03.4211
Gastric Ulcer
[description not available]		03.4211
Duodenal Ulcer
A PEPTIC ULCER located in the DUODENUM.		03.4211
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		03.4211
Cancer of Gallbladder
[description not available]		02.0310
Gallbladder Neoplasms
Tumors or cancer of the gallbladder.		02.0310
Teeth, Impacted
[description not available]		03.4211
Acute Disease
Disease having a short and relatively severe course.		03.4211
Polyarthritis
[description not available]		02.0410
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0410
Arthritis
Acute or chronic inflammation of JOINTS.		02.0410
Colorectal Cancer
[description not available]		02.0410
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0410